The 10 analysts offering 12-month price forecasts for Cymabay Therapeutics Inc have a median target of 11.50, with a high estimate of 14.00 and a low estimate of 7.00. The median estimate represents a +205.04% increase from the last price of 3.77.
The current consensus among 10 polled investment analysts is to Buy stock in Cymabay Therapeutics Inc. This rating has held steady since August, when it was unchanged from a Buy rating.Move your mouse over past months for detail
Earnings and Sales Forecasts
Earnings per Share -$0.27
Reporting Date Mar 24
Earnings per Share
Move your mouse over a quarter or year to see how estimates have changed over time.